Free Trial
Don't Let the A.I. Investing Revolution Pass You By!Ends Tomorrow - Get 30 Days Free

MoonLake Immunotherapeutics (MLTX) Financials

MoonLake Immunotherapeutics logo
$9.89 -0.25 (-2.47%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$9.91 +0.02 (+0.20%)
As of 10/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for MoonLake Immunotherapeutics

Annual Income Statements for MoonLake Immunotherapeutics

This table shows MoonLake Immunotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -4.54 -50 -36 -119
Consolidated Net Income / (Loss)		 -4.54 -65 -44 -121
Net Income / (Loss) Continuing Operations		 -4.54 -65 -44 -121
Total Pre-Tax Income 		-4.54 -64 -44 -121
Total Operating Income		 -4.57 -65 -54 -143
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.57 65 54 143
Selling, General & Admin Expense		 4.57 23 22 30
Research & Development Expense		 - 42 32 113
Total Other Income / (Expense), net		 0.03 0.59 10 22
Other Income / (Expense), net		 - 0.59 10 22
Income Tax Expense		 - 0.04 0.09 0.28
Net Income / (Loss) Attributable to Noncontrolling Interest		 - -15 -8.07 -2.31
Basic Earnings per Share		 ($0.31) ($1.70) ($0.73) ($1.89)
Weighted Average Basic Shares Outstanding		 14.81M 29.36M 49.12M 62.87M
Diluted Earnings per Share		 ($0.31) ($1.70) ($0.73) ($1.89)
Weighted Average Diluted Shares Outstanding		 14.81M 29.36M 49.12M 62.87M
Weighted Average Basic & Diluted Shares Outstanding		 11.93M 52.70M 63.89M 64.01M

Quarterly Income Statements for MoonLake Immunotherapeutics

This table shows MoonLake Immunotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -10 -12 -9.00 -10 -9.43 -7.44 -14 -24 -35 -46
Consolidated Net Income / (Loss)		 -15 -16 -12 -12 -12 -7.89 -14 -25 -36 -46
Net Income / (Loss) Continuing Operations		 -15 -16 -12 -12 -12 -7.89 -14 -25 -36 -46
Total Pre-Tax Income 		-15 -16 -12 -12 -12 -7.84 -14 -25 -36 -46
Total Operating Income		 -15 -17 -13 -13 -13 -15 -20 -31 -43 -50
Total Operating Expenses		 15 17 13 13 13 15 20 31 43 50
Selling, General & Admin Expense		 5.75 5.53 5.52 4.48 5.39 6.93 6.81 6.92 7.38 9.22
Research & Development Expense		 9.02 11 7.42 8.70 7.59 8.10 13 24 36 40
Total Other Income / (Expense), net		 0.04 0.24 0.72 0.84 1.39 7.19 5.92 5.90 7.09 3.23
Other Income / (Expense), net		 0.04 0.24 0.72 0.84 1.39 7.19 5.92 5.90 7.09 3.23
Income Tax Expense		 0.01 0.01 0.01 0.01 0.03 0.04 0.07 0.08 0.09 0.04
Net Income / (Loss) Attributable to Noncontrolling Interest		 -4.63 -4.61 -3.21 -2.21 -2.19 -0.45 -0.30 -0.49 -0.72 -0.79
Basic Earnings per Share		 ($0.27) $2.08 ($0.46) ($0.46) ($0.18) $0.37 ($0.44) ($0.39) ($0.56) ($0.50)
Weighted Average Basic Shares Outstanding		 36.93M 29.36M 78.12M 87.44M 53.52M 49.12M 125.27M 62.87M 62.90M 62.87M
Diluted Earnings per Share		 ($0.27) $2.08 ($0.46) ($0.46) ($0.18) $0.37 ($0.44) ($0.39) ($0.56) ($0.50)
Weighted Average Diluted Shares Outstanding		 36.93M 29.36M 78.12M 87.44M 53.52M 49.12M 125.27M 62.87M 62.90M 62.87M
Weighted Average Basic & Diluted Shares Outstanding		 38.98M 52.70M 52.70M 62.45M 62.45M 63.89M 63.87M 63.88M 63.91M 64.01M

Annual Cash Flow Statements for MoonLake Immunotherapeutics

This table details how cash moves in and out of MoonLake Immunotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -0.67 31 412 -271
Net Cash From Operating Activities		 -0.61 -56 -43 -117
Net Cash From Continuing Operating Activities		 -0.61 -56 -43 -117
Net Income / (Loss) Continuing Operations		 0.00 -65 -44 -121
Consolidated Net Income / (Loss)		 - -65 -44 -121
Depreciation Expense		 - 0.16 0.37 1.38
Non-Cash Adjustments To Reconcile Net Income		 -4.57 9.87 7.08 5.63
Changes in Operating Assets and Liabilities, net		 3.96 -1.43 -6.15 -2.35
Net Cash From Investing Activities		 0.00 -32 -25 -206
Net Cash From Continuing Investing Activities		 0.00 -32 -25 -206
Purchase of Property, Plant & Equipment		 - -0.02 -0.28 -0.52
Purchase of Investments		 0.00 -42 -176 -350
Sale and/or Maturity of Investments		 - 9.90 151 145
Net Cash From Financing Activities		 -0.06 120 480 51
Net Cash From Continuing Financing Activities		 -0.06 120 480 51
Repayment of Debt		 -0.06 -15 0.00 0.00
Repurchase of Common Equity		 0.00 0.00 0.00 -0.00
Issuance of Common Equity		 0.00 0.00 482 53
Other Financing Activities, net		 - 135 -2.75 -1.23
Other Net Changes in Cash		 - 0.01 - 0.13
Cash Income Taxes Paid		 - 0.00 0.04 0.15

Quarterly Cash Flow Statements for MoonLake Immunotherapeutics

This table details how cash moves in and out of MoonLake Immunotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -52 -1.70 11 452 -184 133 7.27 -116 33 -195
Net Cash From Operating Activities		 -9.35 -12 -9.02 -12 -9.25 -12 -15 -28 -25 -48
Net Cash From Continuing Operating Activities		 -9.35 -12 -9.02 -12 -9.25 -12 -15 -28 -25 -48
Net Income / (Loss) Continuing Operations		 -15 -16 -12 -12 -12 -7.89 -14 -25 -36 -46
Consolidated Net Income / (Loss)		 -15 -16 -12 -12 -12 -7.89 -14 -25 -36 -46
Depreciation Expense		 0.00 0.16 0.00 0.00 0.00 0.36 0.02 0.03 0.03 1.30
Non-Cash Adjustments To Reconcile Net Income		 2.64 2.59 2.66 1.41 1.47 1.54 1.85 2.16 2.52 -0.91
Changes in Operating Assets and Liabilities, net		 2.75 2.12 0.53 -1.22 0.89 -6.35 -2.84 -5.32 8.28 -2.47
Net Cash From Investing Activities		 -42 9.90 20 13 -174 117 -29 -88 58 -147
Net Cash From Continuing Investing Activities		 -42 9.90 20 13 -174 117 -29 -88 58 -147
Purchase of Property, Plant & Equipment		 - -0.00 0.00 - - -0.28 -0.21 - -0.13 -0.18
Purchase of Investments		 - 0.00 0.00 - -176 - -88 -86 -29 -147
Sale and/or Maturity of Investments		 - 9.90 20 13 1.36 117 59 -1.30 88 -0.21
Net Cash From Financing Activities		 - 0.00 0.00 451 - 28 51 - 0.18 0.15
Net Cash From Continuing Financing Activities		 - 0.00 0.00 451 - 28 51 - 0.18 0.15
Other Financing Activities, net		 - - 0.00 - - -2.75 -1.56 - 0.18 0.15
Other Net Changes in Cash		 0.07 -0.01 - - 0.01 - - - -0.33 0.42

Annual Balance Sheets for MoonLake Immunotherapeutics

This table presents MoonLake Immunotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 117 9.68 77 527 478
Total Current Assets		 1.62 9.64 77 514 474
Cash & Equivalents		 1.34 8.04 40 451 180
Short-Term Investments		 - 0.00 33 60 268
Accounts Receivable		 - 0.15 0.22 1.06 2.84
Prepaid Expenses		 0.28 1.45 4.18 2.10 23
Plant, Property, & Equipment, net		 0.00 0.05 0.05 0.32 0.72
Total Noncurrent Assets		 115 0.00 0.28 12 2.92
Other Noncurrent Operating Assets		 115 0.00 0.28 12 2.92
Total Liabilities & Shareholders' Equity		 117 9.68 77 527 478
Total Liabilities		 4.15 21 8.08 13 25
Total Current Liabilities		 0.13 21 7.67 9.97 22
Accounts Payable		 - 1.57 0.25 1.84 8.99
Accrued Expenses		 0.07 4.52 7.26 6.93 12
Other Current Liabilities		 - 0.00 0.15 1.20 1.37
Total Noncurrent Liabilities		 4.03 0.24 0.41 3.08 2.08
Noncurrent Employee Benefit Liabilities		 4.03 0.24 0.28 0.58 0.62
Other Noncurrent Operating Liabilities		 - 0.00 0.13 2.50 1.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -2.52 -12 69 513 453
Total Preferred & Common Equity		 -2.52 -12 49 496 447
Total Common Equity		 -2.52 -12 49 496 447
Common Stock		 0.00 42 129 610 677
Retained Earnings		 -2.52 -54 -81 -117 -236
Accumulated Other Comprehensive Income / (Loss)		 - -0.17 0.35 2.36 5.00
Noncontrolling Interest		 - 0.00 20 18 6.57

Quarterly Balance Sheets for MoonLake Immunotherapeutics

This table presents MoonLake Immunotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 89 67 507 500 564 545 518
Total Current Assets		 89 67 506 500 554 537 512
Cash & Equivalents		 41 50 502 318 458 343 376
Short-Term Investments		 42 13 0.00 178 89 177 118
Accounts Receivable		 0.60 0.38 0.62 0.72 1.50 1.68 2.41
Prepaid Expenses		 4.48 3.08 3.96 3.31 5.04 15 16
Plant, Property, & Equipment, net		 0.05 0.05 0.04 0.04 0.51 0.48 0.58
Total Noncurrent Assets		 0.00 0.25 0.21 0.17 10 7.51 5.32
Other Noncurrent Operating Assets		 - 0.25 0.21 0.17 10 7.51 5.32
Total Liabilities & Shareholders' Equity		 89 67 507 500 564 545 518
Total Liabilities		 6.02 7.68 7.51 11 12 15 23
Total Current Liabilities		 6.02 7.28 7.13 10 8.91 12 20
Accounts Payable		 1.06 3.83 4.36 3.40 3.48 5.14 11
Accrued Expenses		 4.96 3.30 2.62 6.75 4.12 5.82 7.93
Other Current Liabilities		 - 0.16 0.16 0.16 1.30 1.32 1.44
Total Noncurrent Liabilities		 0.00 0.41 0.38 0.27 2.82 2.56 2.63
Noncurrent Employee Benefit Liabilities		 0.00 0.31 0.32 0.26 0.46 0.54 0.69
Other Noncurrent Operating Liabilities		 - 0.09 0.05 0.01 2.36 2.02 1.94
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 83 59 499 490 552 530 496
Total Preferred & Common Equity		 55 42 490 425 543 521 488
Total Common Equity		 55 42 490 425 543 521 488
Common Stock		 124 131 590 531 670 672 675
Retained Earnings		 -69 -90 -100 -109 -130 -155 -190
Accumulated Other Comprehensive Income / (Loss)		 0.25 0.34 0.04 2.88 2.69 3.26 2.83
Noncontrolling Interest		 27 17 9.31 65 9.83 9.37 7.31

Annual Metrics And Ratios for MoonLake Immunotherapeutics

This table displays calculated financial ratios and metrics derived from MoonLake Immunotherapeutics' official financial filings.

Metric 2021 2022 2023 2024
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -1,307.00% 32.18% -174.17%
EBIT Growth		 0.00% -1,310.61% 31.77% -175.01%
NOPAT Growth		 0.00% -1,323.56% 16.81% -164.38%
Net Income Growth		 0.00% -1,320.01% 31.67% -175.06%
EPS Growth		 0.00% -448.39% 57.06% -158.90%
Operating Cash Flow Growth		 0.00% -9,046.87% 23.47% -172.54%
Free Cash Flow Firm Growth		 0.00% 0.00% 6.74% -135.71%
Invested Capital Growth		 0.00% 28.52% 174.16% 116.04%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -362.89% 17.06% -45.18%
EBIT Q/Q Growth		 0.00% -364.08% 16.38% -46.71%
NOPAT Q/Q Growth		 0.00% -368.34% 2.99% -31.83%
Net Income Q/Q Growth		 0.00% -376.74% 16.29% -46.54%
EPS Q/Q Growth		 0.00% -218.06% -1.39% -8.00%
Operating Cash Flow Q/Q Growth		 0.00% -225.23% -1.78% -44.90%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -30.08% -22.83%
Invested Capital Q/Q Growth		 0.00% -275.64% 139.18% 240.14%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.06% 100.21% 100.23%
Interest Burden Percent		 99.39% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -9.01% -225.85% -15.14% -25.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,760.81% -2,626.49%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1.27% -147.01% -14.16% -24.45%
Return on Equity Simple (ROE_SIMPLE)		 39.01% -131.92% -8.89% -27.13%
Net Operating Profit after Tax (NOPAT)		 -3.20 -46 -38 -100
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 19.30% -58.21% -2.12% -4.40%
Return On Investment Capital (ROIC_SIMPLE)		 - -66.23% -7.38% -22.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.57 -64 -44 -121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.57 -64 -44 -120
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 11.32 7.61 7.74
Price to Tangible Book Value (P/TBV)		 0.00 11.32 7.61 7.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 1,320.26 562.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 -1.29 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -0.60 -1.14 -1.00 -0.99
Leverage Ratio		 1.25 1.51 1.04 1.04
Compound Leverage Factor		 1.25 1.51 1.04 1.04
Debt to Total Capital		 447.09% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 447.09% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 2.16% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 28.89% 3.47% 1.45%
Common Equity to Total Capital		 -349.25% 71.11% 96.53% 98.55%
Debt to EBITDA		 -3.28 0.00 0.00 0.00
Net Debt to EBITDA		 -1.52 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -4.69 0.00 0.00 0.00
Net Debt to NOPAT		 -2.18 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 -6.61 37.95 173.96 84.21
Noncontrolling Interest Sharing Ratio		 114.12% 34.91% 6.47% 2.52%
Liquidity Ratios		 - - - -
Current Ratio		 0.46 9.98 51.59 21.11
Quick Ratio		 0.39 9.44 51.38 20.07
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -47 -44 -103
Operating Cash Flow to CapEx		 0.00% -349,140.48% -15,029.18% -22,441.34%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -4.68 -3.35 2.48 5.36
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.34 5.83 2.88
Enterprise Value (EV)		 153 501 3,278 3,019
Market Capitalization		 146 553 3,771 3,460
Book Value per Share		 ($0.79) $0.93 $7.94 $6.99
Tangible Book Value per Share		 ($0.79) $0.93 $7.94 $6.99
Total Capital		 3.35 69 513 453
Total Debt		 15 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 6.96 -72 -511 -448
Capital Expenditures (CapEx)		 0.00 0.02 0.28 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.49 -3.27 -6.81 3.80
Debt-free Net Working Capital (DFNWC)		 3.55 69 504 452
Net Working Capital (NWC)		 -11 69 504 452
Net Nonoperating Expense (NNE)		 1.34 19 6.19 21
Net Nonoperating Obligations (NNO)		 6.96 -72 -511 -448
Total Depreciation and Amortization (D&A)		 0.00 0.16 0.37 1.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 ($0.31) ($1.70) ($1.46) ($1.89)
Adjusted Weighted Average Basic Shares Outstanding		 14.81M 29.36M 98.25M 62.87M
Adjusted Diluted Earnings per Share		 ($0.31) ($1.70) ($1.46) ($1.89)
Adjusted Weighted Average Diluted Shares Outstanding		 14.81M 29.36M 98.25M 62.87M
Adjusted Basic & Diluted Earnings per Share		 ($0.31) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.93M 52.70M 63.89M 64.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.20 -46 -38 -100
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MoonLake Immunotherapeutics

This table displays calculated financial ratios and metrics derived from MoonLake Immunotherapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -134.33% -147.29% 23.10% 29.10% 21.33% 54.10% -13.75% -99.77% -210.60% -502.10%
EBIT Growth		 -134.30% -147.74% 23.09% 29.09% 21.33% 52.34% -13.90% -99.95% -210.79% -491.02%
NOPAT Growth		 -135.68% -133.90% 18.89% 25.30% 12.14% 9.99% -53.27% -131.90% -232.23% -229.90%
Net Income Growth		 -134.44% -147.72% 23.05% 29.07% 21.18% 52.10% -14.38% -100.42% -210.81% -488.23%
EPS Growth		 89.73% -60.15% 85.49% -35.29% 33.33% -82.21% 4.35% 15.22% -211.11% -235.14%
Operating Cash Flow Growth		 -363.27% -142.77% 36.38% 41.43% 1.08% -6.45% -65.64% -129.38% -173.22% -292.68%
Free Cash Flow Firm Growth		 0.00% 0.00% -146.21% -104.87% -103.65% -25.55% 71.63% -626.75% -946.91% -129.88%
Invested Capital Growth		 -100.82% 28.52% 94.85% -246.16% -610.93% 174.16% 235.39% 482.21% 124.89% 116.04%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 15.37% -10.67% 25.82% -1.11% 6.10% 35.42% -77.08% -77.58% -45.99% -25.18%
EBIT Q/Q Growth		 15.36% -11.70% 25.82% -1.11% 6.10% 32.33% -77.29% -77.49% -45.96% -28.68%
NOPAT Q/Q Growth		 16.32% -13.04% 22.55% -1.97% 1.59% -15.81% -31.88% -54.28% -40.99% -15.00%
Net Income Q/Q Growth		 15.36% -11.71% 25.80% -1.10% 5.94% 32.12% -77.19% -77.16% -45.87% -28.47%
EPS Q/Q Growth		 20.59% 870.37% -221.05% 0.00% 60.87% 305.56% -22.22% 11.36% -43.59% 10.71%
Operating Cash Flow Q/Q Growth		 54.95% -24.00% 22.18% -34.73% 23.92% -33.44% -21.10% -86.58% 9.38% -91.79%
Free Cash Flow Firm Q/Q Growth		 2.80% -113.06% -526.51% 94.21% 22.94% -349.39% -41.54% -48.26% -11.01% 1.32%
Invested Capital Q/Q Growth		 -148.66% -275.64% -17.62% 32.02% -136.70% 139.18% 114.74% 91.91% -84.59% 240.14%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.06% 100.07% 100.09% 100.08% 100.25% 100.56% 100.51% 100.32% 100.26% 100.09%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -14.04% -225.85% -145.72% -18.79% -18.41% -15.14% -14.99% -11.32% -16.80% -25.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,760.81% -974.90% -662.55% -5,319.84% -2,626.49%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -3.68% -147.01% -115.85% -17.51% -15.45% -14.16% -14.33% -11.11% -15.57% -24.45%
Return on Equity Simple (ROE_SIMPLE)		 -24.47% 0.00% -144.87% -11.39% -12.39% 0.00% -8.45% -11.19% -16.95% 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -12 -9.05 -9.23 -9.08 -11 -14 -21 -30 -35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.42% -14.67% -3.86% -1.05% -0.88% 0.90% -0.03% -0.66% -1.20% -2.44%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.00% - - - -2.05% - - - -7.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -16 -12 -12 -12 -7.84 -14 -25 -36 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -16 -12 -12 -12 -7.48 -14 -25 -36 -45
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 7.40 11.32 26.84 5.49 8.38 7.61 5.91 5.39 6.60 7.74
Price to Tangible Book Value (P/TBV)		 7.40 11.32 26.84 5.49 8.38 7.61 5.91 5.39 6.60 7.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 1,320.26 501.12 224.58 1,733.99 562.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.44 -1.14 -1.96 -1.00 -1.01 -1.00 -1.00 -0.99 -1.00 -0.99
Leverage Ratio		 1.06 1.51 3.57 1.02 1.03 1.04 1.03 1.02 1.03 1.04
Compound Leverage Factor		 1.06 1.51 3.57 1.02 1.03 1.04 1.03 1.02 1.03 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 33.04% 28.89% 28.95% 1.87% 13.22% 3.47% 1.78% 1.77% 1.47% 1.45%
Common Equity to Total Capital		 66.96% 71.11% 71.04% 98.13% 86.78% 96.53% 98.22% 98.23% 98.53% 98.55%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 40.22 40.01 86.60 215.53 202.72 174.19 164.89 114.11 85.49 84.72
Noncontrolling Interest Sharing Ratio		 73.82% 34.91% 20.50% 6.80% 16.08% 6.47% 4.41% 1.82% 7.31% 2.52%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 14.71 9.98 9.14 70.97 48.51 51.59 62.13 43.71 25.51 21.11
Quick Ratio		 13.97 9.44 8.71 70.42 48.19 51.38 61.56 42.46 24.72 20.07
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 100 -13 -82 -4.72 -3.64 -16 -23 -34 -38 -38
Operating Cash Flow to CapEx		 0.00% -1,159,598,200.00% 0.00% 0.00% 0.00% -4,336.91% -7,058.95% 0.00% -19,120.35% -27,609.79%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -0.89 -3.35 -3.94 -2.68 -6.34 2.48 5.33 10 1.58 5.36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -110 1.34 73 -4.51 -5.45 5.83 9.27 13 7.91 2.88
Enterprise Value (EV)		 353 501 1,081 2,195 3,128 3,278 2,672 2,298 2,734 3,019
Market Capitalization		 409 553 1,127 2,688 3,559 3,771 3,209 2,808 3,221 3,460
Book Value per Share		 $1.05 $0.93 $0.80 $9.29 $6.80 $7.94 $8.49 $8.15 $7.64 $6.99
Tangible Book Value per Share		 $1.05 $0.93 $0.80 $9.29 $6.80 $7.94 $8.49 $8.15 $7.64 $6.99
Total Capital		 83 69 59 499 490 513 552 530 496 453
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -83 -72 -63 -502 -496 -511 -547 -520 -494 -448
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.28 0.21 0.00 0.13 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.94 -3.27 -3.83 -2.55 -6.28 -6.81 -2.38 4.80 -1.69 3.80
Debt-free Net Working Capital (DFNWC)		 83 69 59 499 490 504 545 525 492 452
Net Working Capital (NWC)		 83 69 59 499 490 504 545 525 492 452
Net Nonoperating Expense (NNE)		 4.40 4.78 3.17 3.12 2.54 -2.63 0.10 3.35 5.94 12
Net Nonoperating Obligations (NNO)		 -83 -72 -63 -502 -496 -511 -547 -520 -494 -448
Total Depreciation and Amortization (D&A)		 0.00 0.16 0.00 0.00 0.00 0.36 0.02 0.03 0.03 1.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.27) $2.08 ($0.23) ($0.23) ($0.18) $0.37 ($0.44) ($0.39) ($0.56) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding		 36.93M 29.36M 39.06M 43.72M 53.52M 49.12M 125.27M 62.87M 62.90M 62.87M
Adjusted Diluted Earnings per Share		 ($0.27) $2.08 ($0.23) ($0.23) ($0.18) $0.37 ($0.44) ($0.39) ($0.56) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding		 36.93M 29.36M 39.06M 43.72M 53.52M 49.12M 125.27M 62.87M 62.90M 62.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.98M 52.70M 52.70M 62.45M 62.45M 63.89M 63.87M 63.88M 63.91M 64.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -12 -9.05 -9.23 -9.08 -11 -14 -21 -30 -35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

MoonLake Immunotherapeutics (NASDAQ:MLTX) has continued to operate without generating revenue over the recent years, reflecting its profile as a development-stage biopharmaceutical company. The focus appears to be heavily on research and development, which is typical for firms at this stage in the biotech sector.

Positive factors:

  • Consistent investment in research and development expenses, peaking at $40.4 million in Q4 2024, indicating a strong commitment to pipeline advancement.
  • Strong cash and equivalents balance, with $375.7 million at Q3 2024, ensuring liquidity for ongoing operations.
  • Significant financing activities in recent quarters, including equity issuance, with $52.5 million net cash raised in Q1 2024 and another $31.2 million in Q4 2023, supporting capital requirements.
  • Reduction in total operating expenses from $49.58 million in Q4 2024 compared to earlier quarters, which could suggest improved cost controls or strategic shifts.
  • Sizable net cash from investing activities in certain quarters, such as Q4 2023 with $116.9 million, which could relate to strategic asset sales or maturity of investments providing liquidity.

Neutral factors:

  • No reported revenues from products or services in any quarter reviewed, keeping profitability dependent on external funding and future developments.
  • Total assets remain steady around $500 million to $560 million across 2023 and 2024, reflecting stable asset management.
  • Total liabilities remain relatively low (approximately $10 million to $23 million), indicating manageable financial obligations.
  • Weighted average shares outstanding have fluctuated, increasing significantly in Q1 2024, possibly affecting earnings per share calculations.

Negative factors:

  • Substantial and increasing net losses reported quarterly, with losses deepening to approximately $46.4 million in Q4 2024 from $7.9 million in Q4 2023.
  • Negative operating income each quarter, reflecting ongoing cash burn associated with clinical development and operations.
  • Consistent net cash outflows from operating activities, reaching nearly $48.5 million in Q4 2024, raising sustainability concerns without continued funding.
  • Heavy investment activities with significant outflows for purchasing investments, particularly $146.9 million spent in Q4 2024, which may pressure liquidity if not balanced by inflows.
  • Basic and diluted earnings per share have remained negative, widening to -$0.50 in Q4 2024, reflecting increasing losses per share.

Summary: MoonLake Immunotherapeutics shows characteristics of a clinical-stage biotech company with no revenue and significant research and development expenses driving sizable losses each quarter. Despite negative earnings, the company maintains substantial liquidity from cash reserves and capital raises, supporting its current operations and development programs. Investors should monitor cash burn rates and future capital needs, alongside progress in clinical pipelines, to assess the company's path towards commercialization and profitability.

10/16/25 01:15 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About MoonLake Immunotherapeutics' Financials

When does MoonLake Immunotherapeutics' financial year end?

According to the most recent income statement we have on file, MoonLake Immunotherapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has MoonLake Immunotherapeutics' net income changed over the last 3 years?

MoonLake Immunotherapeutics' net income appears to be on an upward trend, with a most recent value of -$121.24 million in 2024, rising from -$4.54 million in 2021. The previous period was -$44.08 million in 2023. Find out what analysts predict for MoonLake Immunotherapeutics in the coming months.

What is MoonLake Immunotherapeutics' operating income?
MoonLake Immunotherapeutics' total operating income in 2024 was -$143.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $143.09 million
How has MoonLake Immunotherapeutics' revenue changed over the last 3 years?

Over the last 3 years, MoonLake Immunotherapeutics' total revenue changed from $0.00 in 2021 to $0.00 in 2024, a change of 0.0%.

How much debt does MoonLake Immunotherapeutics have?

MoonLake Immunotherapeutics' total liabilities were at $24.54 million at the end of 2024, a 88.1% increase from 2023, and a 491.4% increase since 2020.

How much cash does MoonLake Immunotherapeutics have?

In the past 4 years, MoonLake Immunotherapeutics' cash and equivalents has ranged from $1.34 million in 2020 to $451.17 million in 2023, and is currently $180.43 million as of their latest financial filing in 2024.

How has MoonLake Immunotherapeutics' book value per share changed over the last 3 years?

Over the last 3 years, MoonLake Immunotherapeutics' book value per share changed from -0.79 in 2021 to 6.99 in 2024, a change of -983.4%.


Related Companies

This page (NASDAQ:MLTX) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners
URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...
StockEarnings | Sponsoredtc pixel
Generate up to $5,000/month with 10X less money?
The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...
Investors Alley | Sponsoredtc pixel
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...
Brownstone Research | Sponsoredtc pixel
The Final Displacement
A new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...
Porter & Company | Sponsoredtc pixel
Miss This IRS Strategy Now, Regret It Later
With Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...
American Alternative | Sponsoredtc pixel
Nvidia’s slow death march
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...
InvestorPlace | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel